Shattuck Labs’ (STTK) Neutral Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Shattuck Labs (NASDAQ:STTK) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($1.54) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($1.03) EPS.

Other equities research analysts also recently issued research reports about the stock. Evercore ISI raised shares of Shattuck Labs to a “strong-buy” rating in a research report on Wednesday, October 2nd. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a report on Thursday. Finally, Citigroup lowered shares of Shattuck Labs from a “buy” rating to a “neutral” rating and reduced their price target for the company from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Four equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.67.

Shattuck Labs Price Performance

STTK stock opened at $1.24 on Friday. Shattuck Labs has a 1-year low of $1.07 and a 1-year high of $11.76. The business has a fifty day moving average price of $2.08 and a 200-day moving average price of $4.19. The stock has a market capitalization of $58.95 million, a P/E ratio of -0.81 and a beta of 1.85.

Insider Activity at Shattuck Labs

In other news, CEO Taylor Schreiber bought 36,500 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was bought at an average price of $1.21 per share, with a total value of $44,165.00. Following the acquisition, the chief executive officer now owns 71,002 shares of the company’s stock, valued at approximately $85,912.42. This represents a 105.79 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Shattuck Labs

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in Shattuck Labs by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock worth $3,184,000 after purchasing an additional 8,133 shares in the last quarter. Barclays PLC increased its holdings in Shattuck Labs by 299.5% in the 3rd quarter. Barclays PLC now owns 54,311 shares of the company’s stock valued at $189,000 after acquiring an additional 40,717 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in Shattuck Labs in the 3rd quarter worth $144,000. State Street Corp lifted its position in shares of Shattuck Labs by 7.8% in the third quarter. State Street Corp now owns 766,410 shares of the company’s stock worth $2,675,000 after buying an additional 55,579 shares in the last quarter. Finally, Readystate Asset Management LP bought a new position in Shattuck Labs during the third quarter valued at approximately $39,000. Institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.